Wertaschnigg D, Rolnik DL, Nie G, et al. - As preeclampsia (PE) is a significant contributor to maternal and perinatal adverse outcome, researchers here compared asymptomatic women who subsequently developed preterm or term PE vs healthy controls in terms of their serum levels of growth‐differentiation factor 15 (GDF‐15) at three different gestational ages. In this case‐control study, assessment of serum GDF‐15 was done in 300 samples using a commercial GDF‐15 enzyme‐linked immunosorbent assay: 120 samples at 19‐24 weeks of gestation, 120 samples at 30‐34 weeks and 60 samples at 35‐37 weeks. Observations revealed increase in values of GDF‐15 with gestational age.  They indicated no predictive value of serum GDF‐15 levels at 19‐24 or 35‐37 weeks of gestation for preterm or term PE. At 30‐34 weeks, women who subsequently develop preeclampsia had higher GDF‐15 levels; however, this difference is small and GDF‐15 is probably not valuable in clinical practice when used in isolation.